Initial experiments showing that antisense oligonucleotides against fosB reduced dyskinesia were followed by several studies in which LID was exacerbated or reduced by modulating FosB-dependent transcriptional activity. The gene discussed is FOSB; the disease is drug-induced dyskinesia.